Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Eberly, L
Semaglutide the original ~14.9% average body-weight reduction at 52 weeks Targets GLP-1 (one pathway) Weekly injection Best for: first-timers, or anyone sensitive to side effects Tirzepatide the upgrade ~22.1% average body-weight reduction at 52 weeks Targets GLP-1 + GIP (two pathways) Weekly injection Best for: plateaued on semaglutide, or want stronger results Retatrutide the newest ~25.9% average body-weight reduction at 52 weeks Targets GLP-1 + GIP + glucagon (three pathways) Weekly injection Best for: want the newest science, comfortable with a compounded option Semaglutide: the original Semaglutide is a GLP-1 receptor agonist
Heller, W., Musil, H
References Goodman & Gilmans The Pharmacological Basis of Therapeutics Katzung Basic and Clinical Pharmacology Clinical trials data on linagliptin efficacy and safety
